Switzerland, ItalySwitzerland

Cosmo signs licensing deal


Lainate – Cosmo Pharmaceuticals SpA (Lainate, Italy) signed a licensing agreement in mid-October with Ferring Pharmaceuticals (Saint-Prex, Switzerland) for Budesonide MMXTM, an oral corticosteroid for ulcerative colitis that is currently being tested in a Europe-wide phase III trial.
Under the agreement, Ferring receives an exclusive worldwide license (excluding Japan and the US) for distribution of the drug candidate, which is expected to show fewer side effects than other corticoids due to its targeted release in the colon by Cosmo’s multi-matrix system (MMX) drug delivery technology.
In return, Ferring will immediately partner with Cosmo on the multi-centre phase III clinical trials, and will also make an initial payment of a2 million for licensing rights. After market entry, which is scheduled for 2010, Ferring will make revenue-related milestone payments that could potentially reach a58 million over the life of the product. Ferring has also agreed to pay double-digit royalties on net revenue.
According to media reports, a decision on how Cosmo will build its own marketing capabilities in the important US market is expected by the end of the year.



Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...



Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....



Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...



Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...



Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...



Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...



Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...



Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...



Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2015 BIOCOM



All Events


Product of the week


Current issue

All issues